New hope for tough childhood cancers: trial tests aggressive drug combo
NCT ID NCT06561074
Summary
This study is testing whether a combination of three drugs—calaspargase pegol-mknl, decitabine, and venetoclax—can help control aggressive T-cell blood cancers that have returned or not responded to prior treatment in patients aged 1 month to 21 years. The main goals are to see if the treatment leads to complete remission and to carefully monitor its safety. Researchers will also track if patients are healthy enough after treatment to proceed with a potentially curative stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77090, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.